<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-6-5410003901-GGG-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">COVID-19 EDCTP2: European &amp; Dev. Countries Clinical Trials Partnership 2015 - 2019</narrative>
   <narrative xml:lang="SV">COVID-19 EDCTP2: European &amp; Dev. Countries Clinical Trials Partnership 2015 - 2019</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">New/additional funds to address COVID-19
Reprogrammed funds to address COVID-19
Support to European and Developing Countries Clinical Trials          Partnership to accelerate development of new or improved druugs ,     vaccines, microbicides and diagnostics against HIV/AIDS; TB and       malaria. Support provided since 2004. A new expanded programme is     planned within Horizon2020 which will be called EDCTP2.</narrative>
   <narrative xml:lang="SV">Nya medel/medeltill&#xE4;gg f&#xF6;r att bek&#xE4;mpa covid-19
Omprogrammerade medel f&#xF6;r att bek&#xE4;mpa covid-19
BAKGRUND 
Partnerskapet mellan Europa och utvecklingsl&#xE4;nder inom omr&#xE5;det klinisk pr&#xF6;vning (EDCTP) inr&#xE4;ttades 2003 f&#xF6;r att hantera den globala h&#xE4;lsokris som orsakas av de tre st&#xF6;rsta fattigdomsrelaterade sjukdomarna hiv/aids, malaria och tuberkulos och f&#xF6;r att fullg&#xF6;ra EU:s &#xE5;tagande att uppn&#xE5; FN:s millennieutvecklingsm&#xE5;l till 2015. Sverige har genom Sida bidragit med bist&#xE5;ndsmedel till EDCTP och Sida har i enlighet med regeringens beslut den 23 oktober 2003 (UD2003/ 53044/ GU) f&#xF6;retr&#xE4;tt Sverige inom EDCTP:s f&#xF6;rsta program.

F&#xF6;r genomf&#xF6;randet av EDCTP2 har en stiftelse med s&#xE4;te i Haag, Nederl&#xE4;nderna, bildats. Medverkande stater ska utse en myndighet/ institution som f&#xF6;retr&#xE4;dare och medlem i stiftelsen.

Erfarenheterna av svensk medverkan under partnerskapets f&#xF6;rsta program &#xE4;r mycket goda. Regeringen anser att Sveriges engagemang i EDCTP ska forts&#xE4;tta under det andra programmet, och har erh&#xE5;llit riksdagens bemyndigande att besluta om deltagande i den stiftelse som inr&#xE4;ttats som genomf&#xF6;randestruktur f&#xF6;r EDCTP2 (prop. 2014/15:1 utg.omr. 7, bet. 2014/ 15:UU2, rskr. 2014/15:75). Enligt regeringens beslut ska &quot;finansiering av det svenska deltagandet sker genom medel som Sida disponerar inom ramen f&#xF6;r utgiftsomr&#xE5;de 7, anslag 1:1 Bist&#xE5;ndsverksamhet&quot;.

Regeringen har beslutat (Regeringsbeslut UF2015/ 12547/UD/USTYR) att Sverige ska delta och har uppdragit &#xE5;t Sida att f&#xF6;retr&#xE4;da Sverige i den stiftelse som bildats som genomf&#xF6;randestruktur (EDCTP2- IS) f&#xF6;r det andra programmet f&#xF6;r partnerskap mellan Europa och Afrika inom omr&#xE5;det kliniskpr&#xF6;vning (EDCTP2).

Programmet &#xE4;r 10 &#xE5;r, men Sidas beslut handlar enbart om medelstilldelning f&#xF6;r kommande fem&#xE5;rsperiod av EDCTP2 programmet.

I till&#xE4;gg till Sidas bidrag ska Sverige r&#xE4;kna in alla offentliga medel som g&#xE5;r till forskning inom EDCTP2 fokusomr&#xE5;den som del av det totala bidraget. Det inkluderar Sidas bidrag inom globala och bilaterala samarbeten samt Vetenskapsr&#xE5;dets och andra relevanta svenska myndigheters bidrag till forskning inom EDCTP2 fokusomr&#xE5;den. 

UPPDRAGET 
EDCTP syftar till att st&#xF6;dja forskningssamarbete som accelererar den kliniska utvecklingen av nya eller f&#xF6;rb&#xE4;ttrade interventioner f&#xF6;r att f&#xF6;rebygga eller behandla HIV/AIDS, tuberkulos, malaria och andra f&#xF6;rsummade infektionssjukdomar i Afrika s&#xF6;der om Sahara.
  
PROGRAMMET 
Det andra EDCTP-programmet (EDCTP2) genomf&#xF6;rs som en del av det europeiska ramprogrammet f&#xF6;r forskning och Innovation, &#x201D;Horizon 2020&#x201D;.  Europeiska unionens bidrag till EDCTP kan uppg&#xE5; till 683 miljoner euro f&#xF6;r det 10-&#xE5;riga programmet (2014-2024), f&#xF6;rutsatt att detta motsvaras av bidrag fr&#xE5;n de deltagande europeiska staterna.  

DELTAGANDE 
De l&#xE4;nder som deltar i EDCTP2 som medlemmar i f&#xF6;reningen EDCTP i oktober 2015 &#xE4;r: 14 europeiska l&#xE4;nder-&#xD6;sterrike, Danmark, Finland, Frankrike, Tyskland, Irland, Italien, Luxemburg, Nederl&#xE4;nderna, Norge, Portugal, Spanien, Sverige, UK; och 14 afrikanska l&#xE4;nder &#x2013; Burkina Faso, Kamerun, Kongo, Gabon, Gambia, Ghana, Mali, Mo&#xE7;ambique, Niger, Senegal, Sydafrika, Tanzania, Uganda och Zambia. Flera l&#xE4;nder kan komma att ansluta.

STYRELSEFORMER 
EDCTP stiftelsen kommer att genomf&#xF6;ra EDCTP2-programmet. Stiftelsen styrs av sina medlemmar, de deltagande europeiska och afrikanska staterna, genom generalf&#xF6;rsamlingen. Sekretariatet utf&#xF6;r verksamheten inom programmet. Det fr&#xE4;msta vetenskaplig r&#xE5;dgivande organ till generalf&#xF6;rsamlingen och sekretariatet &#xE4;r den r&#xE5;dgivande vetenskaplig kommitt&#xE9; (Scientific Advisory Committee).</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">To accelerate research and development of new or improved diagnostics, drugs, microbicides and vaccines against HIV/AIDS, tuberculosis, malaria and NIDs.</narrative>
  </description>
  <participating-org ref="47000" role="2">
   <narrative xml:lang="EN">EDCTP/European &amp; Developing Countries Clinical Trials Partnership</narrative>
  </participating-org>
  <participating-org ref="47000" role="4" type="40">
   <narrative xml:lang="EN">EDCTP/European &amp; Developing Countries Clinical Trials Partnership</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-6" role="3" type="10">
   <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2015-12-01" type="1"></activity-date>
  <activity-date iso-date="2015-12-01" type="2"></activity-date>
  <activity-date iso-date="2023-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
   </organisation>
   <telephone>+46 8 698 50 00</telephone>
   <email>sida@sida.se</email>
   <website>www.sida.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Valhallav&#xE4;gen 199, 105 25 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.1" vocabulary="3">
   <narrative xml:lang="EN">3.1 - By 2030, reduce the global maternal mortality ratio to less than 70 per 100,000 live births.</narrative>
   <narrative xml:lang="SV">3.1 - Till 2030 minska m&#xF6;drad&#xF6;dligheten i v&#xE4;rlden till mindre &#xE4;n 70 d&#xF6;dsfall per 100 000 f&#xF6;rlossningar med levande barn.</narrative>
  </tag>
  <tag code="3.2" vocabulary="3">
   <narrative xml:lang="EN">3.2 - By 2030, end preventable deaths of newborns and children under 5&#xA0;years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live births.</narrative>
   <narrative xml:lang="SV">3.2 - Senast 2030 s&#xE4;kerst&#xE4;lla att inga sp&#xE4;dbarn eller barn under fem &#xE5;r d&#xF6;r av orsaker som hade kunnat f&#xF6;rebyggas. Alla l&#xE4;nder b&#xF6;r str&#xE4;va efter att minska den neonatala d&#xF6;dligheten till h&#xF6;gst tolv d&#xF6;dsfall per 1 000 levande f&#xF6;dda och d&#xF6;dligheten bland barn under fem &#xE5;r till h&#xF6;gst 25 d&#xF6;dsfall per 1 000 levande f&#xF6;dda.</narrative>
  </tag>
  <tag code="3.3" vocabulary="3">
   <narrative xml:lang="EN">3.3 - By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.</narrative>
   <narrative xml:lang="SV">3.3 - Senast 2030 utrota epidemierna av aids, tuberkulos, malaria och f&#xF6;rsummade tropiska sjukdomar samt bek&#xE4;mpa hepatit, vattenburna sjukdomar och andra smittsamma sjukdomar.</narrative>
  </tag>
  <tag code="3.8" vocabulary="3">
   <narrative xml:lang="EN">3.8 - Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.</narrative>
   <narrative xml:lang="SV">3.8 - &#xC5;stadkomma allm&#xE4;n h&#xE4;lso- och sjukv&#xE5;rd f&#xF6;r alla, som &#xE4;ven skyddar mot ekonomisk risk, tillg&#xE5;ng till grundl&#xE4;ggande h&#xE4;lso- och sjukv&#xE5;rd av god kvalitet liksom tillg&#xE5;ng till s&#xE4;kra, effektiva och ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin av god kvalitet.</narrative>
  </tag>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <tag code="3.C" vocabulary="3">
   <narrative xml:lang="EN">3.c - Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing States.</narrative>
   <narrative xml:lang="SV">3.c - V&#xE4;sentligt st&#xE4;rka finansieringen av h&#xE4;lso- och sjukv&#xE5;rden liksom insatserna f&#xF6;r att rekrytera, utveckla, utbilda och beh&#xE5;lla h&#xE4;lso- och sjukv&#xE5;rdspersonal i utvecklingsl&#xE4;nderna, s&#xE4;rskilt i de minst utvecklade l&#xE4;nderna och sm&#xE5; &#xF6;nationer under utveckling.</narrative>
  </tag>
  <tag code="3.D" vocabulary="3">
   <narrative xml:lang="EN">3.d - Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.</narrative>
   <narrative xml:lang="SV">3.d - St&#xE4;rka alla l&#xE4;nders, i synnerhet utvecklingsl&#xE4;ndernas, kapacitet n&#xE4;r det g&#xE4;ller tidig varning, riskreducering och hantering av nationella och globala h&#xE4;lsorisker.</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="B03" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2015-01-01"></period-start>
   <period-end iso-date="2015-12-28"></period-end>
   <value currency="USD" value-date="2015-01-01">2965845.3252345985</value>
  </budget>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">4382633.085958044</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">4387504.387504387</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">0</value>
  </budget>
  <budget>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">2643851.9865903826</value>
  </budget>
  <budget>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">522568.596154055</value>
  </budget>
  <budget>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">3226690.2960277023</value>
  </budget>
  <planned-disbursement>
   <period-start iso-date="2015-01-01"></period-start>
   <period-end iso-date="2015-12-28"></period-end>
   <value currency="USD" value-date="2015-01-01">2965845.3252345985</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">4382633.085958043</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">4387504.387504388</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">-2e-10</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">2643851.9865903826</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">522568.5961540549</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">3226690.2960277023</value>
  </planned-disbursement>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-01"></transaction-date>
   <value currency="USD" value-date="2015-12-01">18683366.353077</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-28"></transaction-date>
   <value currency="USD" value-date="2015-12-28">2965845.3252345985</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-10-28"></transaction-date>
   <value currency="USD" value-date="2016-10-28">2921755.390638696</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-12-28"></transaction-date>
   <value currency="USD" value-date="2016-12-28">1460877.695319348</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-12-28"></transaction-date>
   <value currency="USD" value-date="2017-12-28">4387504.387504388</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-05-28"></transaction-date>
   <value currency="USD" value-date="2019-05-28">1321925.9932951913</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-09-28"></transaction-date>
   <value currency="USD" value-date="2019-09-28">1321925.9932951913</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-03-28"></transaction-date>
   <value currency="USD" value-date="2020-03-28">344604.0587641291</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-11-28"></transaction-date>
   <value currency="USD" value-date="2020-11-28">145607.3487735757</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-28"></transaction-date>
   <value currency="USD" value-date="2020-12-28">32357.1886163502</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-05-28"></transaction-date>
   <value currency="USD" value-date="2021-05-28">3226690.2960277023</value>
  </transaction>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_047203-15GrantagreementfortheuseofSidascashcontributiontotheEDCTPsecretariat1754307_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Avtal insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2)</narrative>
   </title>
   <category code="A09"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_008722-20AmendmenttotheAgreementontheuseofSida&apos;sCash_ContributiontotheEDCTPS2645574_1_1.pdf">
   <title>
    <narrative xml:lang="SV">&#xC4;ndring avtal insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) 2020_1</narrative>
   </title>
   <category code="A09"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_019264-20AvtalsandringEDCTP2,(54100039)2699410_1_1.pdf">
   <title>
    <narrative xml:lang="SV">&#xC4;ndring avtal insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) 2020_2</narrative>
   </title>
   <category code="A09"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_041561-20RequestforfundingandAmendmenttotheagreementontheuseofSida&apos;scashcon2813693_1_1.pdf">
   <title>
    <narrative xml:lang="SV">&#xC4;ndring avtal insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) 2020_3</narrative>
   </title>
   <category code="A09"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_013221-21AmendmenttotheAgreementontheuseofSida&apos;sCash_ContributiontotheEDCTPS2906783_1_1.pdf">
   <title>
    <narrative xml:lang="SV">&#xC4;ndring avtal insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) 2021</narrative>
   </title>
   <category code="A09"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_044880-15Beslutominsats,EDCTP2_EuropeanandDevelopingCountriesClinicalTrialsPart1718343_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Beslut om insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2)</narrative>
   </title>
   <category code="A11"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_011501-21BeslutomandringavinsatsEDCTP2-Europeananddevelopmentcountriesclinical2897506_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Beslut om &#xE4;ndring av insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) 2021</narrative>
   </title>
   <category code="A11"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_007003-20BeslutomandringavinsatsEDCTP2_European-Dev2632361_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Beslut om &#xE4;ndring av insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2)</narrative>
   </title>
   <category code="A11"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_017172-20BeslutomandringavinsatsEDCTP2_European-Dev2689696_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Beslut om &#xE4;ndring av insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2)</narrative>
   </title>
   <category code="A11"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/54100039_040495-20Beslutomandringavinsats,EDCTP2_European-DevCountriesClinicalTrialsPa2808767_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Beslut om &#xE4;ndring av insats European and Developing Countries Clinical Trials Partnership 2 (EDCTP2)</narrative>
   </title>
   <category code="A11"></category>
  </document-link>
  <result aggregation-status="0" type="2">
   <title>
    <narrative xml:lang="EN">Results achieved</narrative>
    <narrative xml:lang="SV">Uppn&#xE5;dda resultat</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">2020 was the final year in which new calls were launched, to allow enough time for trials to conclude before the end of this programme and for plans to be put in place for a seamless transition to its successor programme. The COVID-19 pandemic had a significant impact on both central EDCTP operations and recruitment in the field. Nevertheless, despite the need for remote working and other challenges, all EDCTP&#x2019;s planned funding-related activities were carried out in 2020. Inevitably, however, the pandemic has also drawn attention and resources away from other infectious diseases, significantly setting back control efforts.
EDCTP demonstrated its value to address the pandemic through its investments in research capacity-building. The response to COVID-19 in sub-Saharan Africa depended to a great extent on the repurposing of capacity put in place to investigate other infectious diseases. Laboratories were rapidly been adapted so to undertake testing for SARS-CoV-2, including mobile laboratories for testing in the community. Demographic surveillance systems established for other diseases formed the bedrock for COVID-19 epidemiologic surveillance and response. Scientific expertise was also been repurposed, many researchers working on infectious diseases have turned their attention to understanding COVID-19 and supporting national responses to the pandemic. EDCTP fellows played key roles in many countries, acting as national advisers on COVID-19 and setting up testing programmes.
EDCTP regional Networks of Excellence helped to enhance countries&#x2019; abilities to manage the pandemic, and raised awareness of its impact on other infectious diseases. In response to the pandemic, EDCTP rapidly activated its emergency funding mechanism, supporting 26 (10 of them with Sida funding) projects exploring key issues and possible control strategies. Most of these projects built on existing collaborations between institutions in sub-Saharan Africa and Europe and took advantage of clinical research infrastructure provided by previous EDCTP funding.
In the area of prevention, Sida is supporting vaccine development projects in HIV (2), malaria (2), and diarrhoeal diseases (3). None of these trials has yet completed all phases of clinical investigation.
In the area of diagnostic research, Sida co-funded a tuberculosis project that evaluates eight promising new diagnostic approaches for childhood tuberculosis.&#xA0;
In the area of therapeutics, Sida co-funded projects related to HIV and HIV-associated infections (3), malaria (2) and tuberculosis (1). One of the HIV projects is evaluating two first-line antiretroviral treatment regimens in pregnant women living with HIV in Uganda and Ethiopia. There have been major delays to the implementation of this project due to difficulties obtaining clinical trials insurance followed by disruption caused by COVID-19.&#xA0;
In the area of epidemic preparedness, one of the COVID-related projects involved pilot funding to establish a platform that could facilitate the rapid initiation of multicentre international trials in the region. This funding contributed to finalising the study protocol and facilitating expedited reviews by in-country regulatory and ethics authorities. It also supported the timely preparation of trial sites in selected African countries and a robust, standardised data management system. The ANTICOV Consortium, coordinated by the Drugs for Neglected Disease Initiative (DNDi), went on to secure major additional funding, and in November 2020, launched the largest clinical trial in Africa of treatments for mild to moderate COVID-19, spanning 13 countries. By treating COVID-19 patients at an early stage, this trial will identify promising drugs to stop the development of severe illness, reduce transmission of the infection, and safeguard hospital resources for those who need them most.
In the area of ethics and regulatory capacities and pharmacovigilance, Sida funding has been invested in seven projects to strengthen regulatory and ethical review and improving national pharmacovigilance capacity in sub-Saharan Africa; five of the projects were completed. In one of the projects, a Clinical Research Information Management System (CRIMS) was established, an online platform that supports Ugandan national regulatory agencies and research ethics committees in their regulatory oversight of clinical research in the country.&#xA0;
A baseline assessment of pharmacovigilance systems and infrastructure was conducted in Ethiopia, Kenya, Tanzania, and Rwanda to identify pharmacovigilance capacity-building priorities. Based on the findings, the National Medicines Regulatory Authorities in each country have developed national pharmacovigilance plans and initiated their implementation. In each of the four countries the project conducted active safety surveillance of one targeted mass drug administration&#xA0;for treatment and prevention and of national immunisation programmes.</narrative>
   </description>
   <indicator ascending="0" measure="5">
    <title>
     <narrative xml:lang="EN">Not applicable</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">No indicator available - only a description of the activity results is published</narrative>
    </description>
   </indicator>
  </result>
  <crs-add>
   <other-flags code="2" significance="1"></other-flags>
  </crs-add>
  <contribution contributionid="54100039" xmlns="http://sida.se/ns/contribution#"></contribution>
  <strategies xmlns="http://sida.se/ns/strategies#">
   <strategy code="1140102" currency="SEK" strategy-amount="0.0" strategy-end-date="2022-12-31" strategy-start-date="2015-01-01">
    <title>Research cooperation 2015-2022</title>
    <titleSV>Forskningssamarbete 2015-2022</titleSV>
   </strategy>
  </strategies>
 </iati-activity>
</iati-activities>
